BioScience Trends
Online ISSN : 1881-7823
Print ISSN : 1881-7815
Advance online publication
Showing 1-8 articles out of 8 articles from Advance online publication
  • Lisha Li, Yan Sun, Na Zhang, Xuemin Qiu, Ling Wang, Qingyan Luo
    Article ID: 2018.01291
    Published: 2019
    [Advance publication] Released: February 17, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    Sufentanil is a type of opioid analgesic and is usually used to facilitate painless labor in combination with the local anesthetic ropivacaine. One aim of the current study was to investigate the effects of sufentanil and ropivacaine on umbilical cord mesenchymal stem cells (UCMSCs). A second aim of this study was to determine whether sufentanil attenuated the cytotoxicity of ropivacaine in vitro. UCMSCs were divided into 3 groups: one was treated with ropivacaine at a concentration of 50, 100, 200, or 400 μg/mL, another was treated with sufentanil at a concentration of 0.5, 5, 50, or 500 nmol/L, and a third was treated with a combination of ropivacaine at a concentration of 200 μg/mL and sufentanil at a concentration of 0.5, 5, 50, or 500 nmol/L. Results indicated that cell proliferation decreased in cells treated with ropivacaine while it increased in cells treated with sufentanil. In addition, sufentanil limited the inhibitory effect of ropivacaine on UCMSC growth in a dose- and time-dependent manner. Combined treatment with ropivacaine at a concentration of 200 μg/mL and sufentanil at a concentration of 500 nmol/L decreased the proportion of dead and apoptotic UCMSCs, and fewer cells were arrested in the S phase compared to cells treated with ropivacaine. Sufentanil inhibited the apoptosis induced by ropivacaine by increasing miR-182-5p, which regulated the expression of mRNA of the pro-apoptotic genes B-cell lymphoma/leukemia 10 (BCL10) and cytochrome c, somatic (CYCS). Sufentanil also increased the expression of mRNA of anti-apoptotic genes. In short, ropivacaine inhibits the cell viability and induces the apoptosis of UCMSCs in vitro while sufentanil attenuates this apoptosis by regulating miR182-5p/BCL10/CYCS.

    Download PDF (2569K)
  • Fei Yu, Lei Gong, Zheng Mo, Wenran Wang, Meilong Wu, Jianghui Yang, Qi ...
    Article ID: 2019.01003
    Published: 2019
    [Advance publication] Released: February 15, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    Immunotherapy might be an effective treatment in extrahepatic cholangiocarcinoma (eCCA), a tumor with extremely limited therapeutic options. Our study is to characterize the programmed death ligand-1 (PD-L1) protein expression and cancer microenvironment profiles in surgically resected eCCA samples. PD-L1 positivity was observed on tumor cells (32.3%) as well as on tumor-associated macrophages (74.2%). PD-L1 expression by eCCA correlated significantly with immune parameters such as intra-tumoral CD3+ tumor infiltrating lymphocytes (TILs) density (P = 0.002), intra-tumoral CD8+ TILs density (P < 0.001), and the expression pattern of human leukocyte antigen (HLA) class I (P < 0.001). Immunofluorescence showed that PD-L1 positive tumor cells were adjacent to PD-1 positive cells and the stroma covered with interferon-γ. Correlation with clinicopathological parameters and survival analyses revealed that PD-L1 positivity in eCCA was related to the absence of venous invasion (P = 0.030), improved overall survival (P = 0.020) and progressionfree survival (P = 0.011). HLA class I molecules defect, which is an important mechanism of immune evasion, was frequently observed in eCCA (50.0%) and was associated with a decreased number of intra-tumoral CD8+ TIL density (P = 0.028). Additionally, the presence of unusually high numbers of tumor-associated macrophages (TAMs) subsets M2 in most of eCCA (74.2%) was noted. Our study indicated that PD-L1 expression in association with intra-tumoral TILs infiltration and HLA class I expression in 32.3% of the eCCA reflects an active immune microenvironment potentially responsive to PD-1/PD-L1 inhibitors. In addition, the combination of macrophage-targeting agents may provide therapeutic synergy for future immunotherapy.

    Download PDF (7379K)
  • Xiaochen Chen, Xing Liu, Renhai Tang, Runhua Ye, Yuecheng Yang, Shitan ...
    Article ID: 2018.01299
    Published: 2019
    [Advance publication] Released: February 05, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    End-stage liver disease (ESLD) is among leading causes of death for people living with HIV and HCV. Little is known how liver fibrosis score predicts mortality in HIV/HCV co-infected population under combination antiretroviral therapy (cART). A retrospective cohort study of 691 HIV/HCV co-infected patients receiving cART in Yunnan, China from 2005 to 2016 was carried out to explore the association between Fibrosis-4 index (FIB-4) and all-cause mortality. Cox proportional hazard models were used to estimate the hazard ratios (HRs) for FIB-4 and covariates. After a median follow-up of 4.8 years with a total follow-up time of 3,696 person-years (PY), 131 deaths occurred and the all-cause mortality was 3.5 per 100 PY. The mortality was 2.9 (95% CI: 2.3-3.5)/100 PY for the FIB-4 ≤ 3.25 group and 5.8 (4.2-7.4)/100 PY for the FIB-4 > 3.25 group at baseline. People with FIB-4 changed from mild to advanced group showed HR of 1.81 (95% CI: 1.01-3.25) for death, and with FIB-4 sustaining advanced showed HR of 3.11 (1.75-5.54), both compared to those with FIB-4 remained mild, while lower risk of death was observed among married people (HR = 0.63, 95% CI: 0.41-0.99) compared to unmarried, among those with most recent CD4+ T cell counts between 200 and 350 cells/μL (0.50, 0.30-0.86) and > 350 cells/μL (0.25, 0.15-0.41) compared to CD4 under 200 cells/μL. Advanced and progressive liver fibrosis is a strong predictor of all-cause mortality in HIV/HCV co-infected patients under cART in China.

    Download PDF (489K)
  • Yoshiki Oda, Kohsuke Saito, Munehiro Nakata
    Article ID: 2019.01008
    Published: 2019
    [Advance publication] Released: January 30, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    The current study determined the structure of a hemolytic compound found in an extract from the fruiting bodies of the edible mushroom Hypsizygus marmoreus when its pH was lowered. The hemolytic compound was purified using the modified Bligh and Dyer method followed by chromatography using reversed phase and silica gel columns. Structural analyses of the purified hemolytic compound were performed using NMR and ESI-MS. The deduced structure indicated a trans,trans-5,8-docosadienoic acid calcium salt. Although numerous proteinous hemolysins from various mushrooms have been described, the current study is the first to report on a low-molecular-weight hemolytic compound derived from an H. marmoreus extract.

    Download PDF (550K)
  • Qi Tang, Min Liu, Hongzhou Lu
    Article ID: 2019.01009
    Published: 2019
    [Advance publication] Released: January 25, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    Prevention of mother-to-child transmission (PMTCT) program offer a range of services for women of reproductive age living with or at risk of contracting the human immunodeficiency virus (HIV) in order to maintain their health and to protect their infants from acquiring HIV. The program has made significant progress in eliminating HIV. Thanks to the provision of PMTCT services, around 1.4 million HIV infections among children were prevented between 2010 and 2018. PMTCT program in China has developed substantially over the past few years, highlighting the national response to HIV/AIDS. Although huge strides have been made in PMTCT, a number of important issues, such as prevention at each step, monitoring of PMTCT services, and early infant diagnosis, need to be addressed in the future.

    Download PDF (203K)
  • Norihiro Kokudo, Tetsuo Hara
    Article ID: 2019.01018
    Published: 2019
    [Advance publication] Released: January 25, 2019
    JOURNALS FREE ACCESS ADVANCE PUBLICATION

    "History, Tradition, and Progress", a grand ceremony in celebration of the 150th Anniversary of the National Center for Global Health and Medicine (NCGM) was held in Tokyo, Japan on December 3, 2018. Hundreds of distinguished guests from home and abroad attended the grand ceremony. The NCGM is a national research and development agency, which is a type of independent administrative entity. The NCGM originated from a temporary army hospital that was established in Tokyo in October 1868. After several rounds of restructuring and reorganization, the facility became the NCGM in April 2015. The NCGM has various departments, including the Center Hospital, Kohnodai Hospital, the Research Institute, the Center for Clinical Sciences, the Bureau of International Health Cooperation, and the National College of Nursing. The NCGM conducts research in various fields such as infectious diseases, immune disorders, diabetes, and metabolic disorders and it provides advanced and comprehensive medical care. The NCGM also comprehensively provides training for personnel in international cooperation and medicine. "As a research and development entity, the NCGM will continue to fulfil those tasks in accordance with Japan's national policies", Dr. Norihiro Kokudo, the president of NCGM, said in his speech of anniversary opening greeting.

    Download PDF (736K)
  • Harshal S Mandavdhare, Vishal Sharma, Harjeet Singh, Usha Dutta
    Article ID: 2018.01028
    Published: 2018
    [Advance publication] Released: July 15, 2018
    JOURNALS RESTRICTED ACCESS ADVANCE PUBLICATION
    This withdrawal is for above article due to the misoperation of advance online publication.
    Download PDF (688K)
  • Olivier Audet, Hung Tien Bui, Maxime Allisse, Alain-Steve Comtois, Mar ...
    Article ID: 2018.01060
    Published: 2018
    [Advance publication] Released: July 15, 2018
    JOURNALS RESTRICTED ACCESS ADVANCE PUBLICATION
    This withdrawal is for above article due to the misoperation of advance online publication.
    Download PDF (543K)
feedback
Top